US Stock Futures Edge Higher Ahead Of Alcoa Earnings, Fed Minutes - Alcoa (NYSE:AA), BioCryst Pharma (NASDAQ:BCRX)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Pre-open moversUS stock futures traded higher in early pre-market trade. The Federal Open Market Committee will issue minutes of its meeting at 2:00 p.m. ET. Alcoa (NYSE: AA) is projected to post its Q3 earnings at $0.23 per share on revenue of $5.85 billion. Futures for the Dow Jones Industrial Average surged 16 points to 16,667.00, while the Standard & Poor's 500 index futures rose 3.50 points to 1,931.40. Futures for the Nasdaq 100 index gained 5.25 points to 3,961.50.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

A Peek Into Global Markets European markets were lower today, with the Spanish Ibex Index falling 0.04%, STOXX Europe 600 Index dropping 0.54%. German DAX 30 index fell 0.44%, French CAC 40 Index slipped 0.34% and London's FTSE 100 Index dropped 0.18%.In Asian markets, Japan's Nikkei Stock Average dropped 1.19%, Hong Kong's Hang Seng Index declined 0.68%, China's Shanghai Composite Index jumped 0.80% and India's BSE Sensex fell 0.10%. The HSBC China services PMI fell to 53.5 in September, versus 54.1 in August..Broker Recommendation

Analysts at Raymond James upgraded Cogent Communications Group (NASDAQ: CCOI) from Market Perform to Outperform. The price target for Cogent Communications is set to $153. Cogent Communications' shares closed at $30.57 yesterday.Breaking news

Galena Biopharma (NASDAQ: GALE) today announced the Notice of Allowance of a U.S. patent application covering methods of treating patients having any HER2/neu expressing cancer by administering NeuVax™ (nelipepimut-S) in combination with Herceptin® (trastuzumab; Genentech/Roche). To read the full news, click here.
Engility (NYSE: EGL) today announced Engility has been awarded a $9.2 million contract by the United States Marine Corps (USMC) to support the Director of Intelligence (DIRINT) in developing and sustaining the Marine Corps' Intelligence, Surveillance, and Reconnaissance Enterprise (MCISR-E). To read the full news, click here.
BioCryst Pharmaceuticals (NASDAQ: BCRX) today announced that clinical trial results related to its investigational drug RAPIVAB (peramivir injection), an intravenous (I.V.) neuraminidase inhibitor for the treatment of influenza, will be presented at the IDWeek Conference in Philadelphia October 8-12, 2014. To read the full news, click here.
Chimerix (NASDAQ: CMRX) announced today preliminary data for its investigational antiviral brincidofovir (BCV, CMX001) showing improved survival for patients with adenovirus in the open-label pilot portion of the Phase 3 AdVise Trial. To read the full news, click here.